Among in vivo tested compounds, RES and proanthocyanidin-rich extracts prevented tumorigenesis in sporadic CRC models by suppressing Kras activity (Saud et al., 2014) and inflammatory pathways (Derry et al., 2013), through miR modulation. The gene discussed is KRAS; the disease is colorectal carcinoma.